The role of b-type natriuretic peptide in heart failure management

Australian Critical Care

Volumn 22, Issue 3, 2009, Pages 117-123

  Newton, Phillip J ^a   Betihavas, Vasiliki ^a   Macdonald, Peter ^b  

^a CURTIN UNIVERSITY   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

b Type natriuretic peptide; Heart failure

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE;

ARTICLE; BLOOD; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; HEART FAILURE; HUMAN; NURSING; PREDICTION AND FORECASTING; RISK ASSESSMENT; RISK FACTOR;

BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS;

EID: 68149132476     PISSN: 10367314     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.aucc.2009.06.001     Document Type: Article

References (46)

1. Australian Institute of Health & Welfare. Heart, stroke and vascular diseases: Australian facts. Canberra; 2004. Report No.: AIHW Cat. No. CVD 27.
2. Clark R.A., Mclennan S., Dawson A., Wilkinson D., and Stewart S. Uncovering a hidden epidemic: a study of the current burden of heart failure in Australia. Heart Lung Circ 13 (2004) 266-273
3. Davidson P., Newton P., and Macdonald P. Chronic heart failure. In: Chang E., and Johnson A. (Eds). Chronic illness and disability (2008), Elsevier 318-333
4. Abhayaratna W.P., Smith W.T., Becker N.G., Marwick T.H., Jeffery I.M., and McGill D.A. Prevalence of heart failure and systolic ventricular dysfunction in older Australians: The Canberra Heart Study. Med J Aust 184 4 (2006) 151-154
5. Krum H., and Stewart S. Chronic heart failure: time to recognize this major public health problem. Med J Aust 184 4 (2006) 147-148
6. National Heart Foundation of Australia, Cardiac Society of Australia & New Zealand. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand (Chronic Heart Failure Guidelines Expert Writing Panel). Guidelines for the prevention, detection and management of chronic heart failure in Australia; 2006.
7. Phillips S.M., Marton R.L., and Tofler G. Barriers to diagnosing and managing heart failure in primary care. Med J Aust 181 2 (2004) 78-81
8. Maisel A., Mueller C., Adams Jr. K., Anker S.D., Aspromonte N., Cleland J.G.F., et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 10 9 (2008) 824-839
9. Daniels L.B., and Maisel A.S. Natriuretic peptides. J Am Coll Cardiol 50 25 (2007) 2357-2368
10. Sudoh T., Minamino N., Kangawa K., and Matsuo H. Brain natriuretic peptide-32: N-terminal six amino acid extended form of brain natriuretic peptide identified in porcine brain. Biochem Biophys Res Commun 155 2 (1988) 726-732
11. Martinez-Rumayor A., Richards A.M., Burnett J.C., and Januzzi Jr. J.L. Biology of the natriuretic peptides. Am J Cardiol 101 3 Suppl. 1 (2008) S3-S8
12. Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail 6 3 (2004) 257-260
13. Kucher N., Printzen G., and Goldhaber S.Z. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation 107 20 (2003) 2545-2547
14. Nagaya N., Nishikimi T., Okano Y., Uematsu M., Satoh T., Kyotani S., et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 31 1 (1998) 202-208
15. Knudsen C.W., Omland T., Clopton P., Westheim A., Wu A.H.B., Duc P., et al. Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients: an analysis from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 46 5 (2005) 838-844
16. Schou M., Dalsgaard M.K., Clemmesen O., Dawson E.A., Yoshiga C.C., Nielsen H.B., et al. Kidneys extract BNP and NT-proBNP in healthy young men. J Appl Physiol 99 5 (2005) 1676-1680
17. Goetze J.P., Jensen G., ller S., Bendtsen F., Rehfeld J.F., and Henriksen J.H. BNP and N-terminal proBNP are both extracted in the normal kidney. Eur J Clin Investig 36 (2006) 8-15
18. Maisel A.S., Krishnaswamy P., Nowak R.M., McCord J., Hollander J.E., Duc P., et al. Rapid measurement of b-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347 3 (2002) 161-167
19. Mueller C., Laule-Kilian K., Frana B., Rodriguez D., Rudez J., Scholer A., et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 350 7 (2004) 647-654
20. Januzzi Jr. J.L., Camargo C.A., Anwaruddin S., Baggish A.L., Chen A.A., Krauser D.G., et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95 8 (2005) 948-954
21. Ewald B., Ewald D., Thakkinstian A., and Attia J. Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction. Intern Med J 38 2 (2008) 101-113
22. Vasan R.S., Benjamin E.J., Larson M.G., Leip E.P., Wang T.J., Wilson P.W.F., et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: The Framingham Heart Study. JAMA 288 10 (2002) 1252-1259
23. Silver M.A., Maisel A., Yancy C.W., McCullough P.A., Burnett Jr. J.C., Francis G.S., et al. BNP Consensus Panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail 10 5 Suppl. 3 (2004) 1-30
24. Hamada Y., Tanaka N., Murata K., Takaki A., Wada Y., Oyama R., et al. Significance of predischarge BNP on one-year outcome in decompensated heart failure-comparative study with echo-Doppler indexes. J Card Fail 11 1 (2005) 43-49
25. Kirk V., Bay M., Parner J., Krogsgaard K., Herzog T.M., Boesgaard S., et al. N-terminal proBNP and mortality in hospitalised patients with heart failure and preserved vs. reduced systolic function: data from the prospective Copenhagen Hospital Heart Failure Study (CHHF). Eur J Heart Fail 6 3 (2004) 335-341
26. Masson S., Latini R., Anand I.S., Vago T., Angelici L., Barlera S., et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: The Valsartan Heart Failure (Val-HeFT) data. Clin Chem 52 8 (2006) 1528-1538
27. Hartmann F., Packer M., Coats A.J.S., Fowler M.B., Krum H., Mohacsi P., et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 110 13 (2004) 1780-1786
28. Richards A., Doughty R., Nicholls M., MacMahon S., Sharpe N., Murphy J., et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol 37 7 (2001) 1781-1787
29. Daniels L.B., Bhalla V., Clopton P., Hollander J.E., Guss D., McCullough P.A., et al. B-type natriuretic peptide (BNP) levels and ethnic disparities in perceived severity of heart failure: results from the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT) multicenter study of BNP levels and emergency department decision making in patients presenting with shortness of breath. J Card Fail 12 4 (2006) 281-285
30. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., Mahoney D.W., Bailey K.R., and Burnett Jr. J.C. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 40 5 (2002) 976-982
31. Wang T.J., Larson M.G., Levy D., Leip E.P., Benjamin E.J., Wilson P.W.F., et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 90 3 (2002) 254-258
32. Rutten F.H., and Hoes A.W. B-type natriuretic peptide assays for detecting heart failure in the elderly: same value as those in the younger?. Int J Cardiol 125 2 (2008) 161-165
33. Maisel A.S., Clopton P., Krishnaswamy P., Nowak R.M., McCord J., Hollander J.E., et al. Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study. Am Heart J 147 6 (2004) 1078-1084
34. Maisel A. B-type natriuretic peptide levels: diagnostic and therapeutic potential. Cardiovasc Toxicol 1 2 (2001) 159-164
35. Januzzi J.L., van Kimmenade R., Lainchbury J., Bayes-Genis A., Ordonez-Llanos J., Santalo-Bel M., et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: The International Collaborative of NT-proBNP Study. Eur Heart J 27 3 (2006) 330-337
36. DeFilippi C., van Kimmenade R.R.J., and Pinto Y.M. Amino-terminal pro-b-type natriuretic peptide testing in renal disease. Am J Cardiol 101 3 Suppl. 1 (2008) S82-S88
37. Horwich T.B., Hamilton M.A., and Fonarow G.C. B-type natriuretic peptide levels in obese patients with advanced heart failure. J Am Coll Cardiol 47 1 (2006) 85-90
38. Krauser D.G., Lloyd-Jones D.M., Chae C.U., Cameron R., Anwaruddin S., Baggish A.L., et al. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. Am Heart J 149 4 (2005) 744-750
39. Bayes-Genis A., DeFilippi C., and Januzzi Jr. J.L. Understanding amino-terminal pro-b-type natriuretic peptide in obesity. Am J Cardiol 101 3 Suppl. 1 (2008) S89-S94
40. Brenden C.K., Hollander J.E., Guss D., McCullough P.A., Nowak R., Green G., et al. Gray zone BNP levels in heart failure patients in the emergency department: results from the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT) multicenter study. Am Heart J 151 5 (2006) 1006-1011
41. Packer M. Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure?. Circulation 108 24 (2003) 2950-2953
42. O'Hanlon R., O'Shea P., Ledwidge M., O'Loughlin C., Lange S., Conlon C., et al. The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. J Card Fail 13 1 (2007) 50-55
43. Jourdain P., Jondeau G., Funck F., Gueffet P., Le Helloco A., Donal E., et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: The STARS-BNP Multicenter Study. J Am Coll Cardiol 49 16 (2007) 1733-1739
44. Pfisterer M., Buser P., Rickli H., Gutmann M., Erne P., Rickenbacher P., et al. BNP-guided vs symptom-guided heart failure therapy: The Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 301 4 (2009) 383-392
45. Topol E.J. Nesiritide-not verified. N Engl J Med 353 2 (2005) 113-116
46. Yancy C.W., Krum H., Massie B.M., Silver M.A., Stevenson L.W., Cheng M., et al. Safety and efficacy of outpatient Nesiritide in patients with advanced heart failure: results of the second follow-up serial infusions of Nesiritide (FUSION II) trial. Circ Heart Fail 1 1 (2008) 9-16